Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Journal of immunology (Baltimore, Md. : 1950) - 1 Nov 2014

Singh Manisha, Khong Hiep, Dai Zhimin, Huang Xue-Fei, Wargo Jennifer A, Cooper Zachary A, Vasilakos John P, Hwu Patrick, Overwijk Willem W

Abstract excerpt

Intratumoral immune activation can induce local and systemic antitumor immunity. Imiquimod is a cream-formulated, TLR7 agonist that is Food and Drug Administration approved for the treatment of nonmelanoma skin cancers, but it has limited activity against melanoma. We studied the antitumor activity and mechanism of action of a novel, injectable, tissue-retained TLR7/8 agonist, 3M-052, which avoids systemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptive Immunity
Share to Chemokine CCL2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma, Experimental

Share to Toll-Like Receptor 7

Share to Toll-Like Receptor 8

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 25252955
DOI: 10.4049/jimmunol.1401160
PMCID: PMC4201984

Genes

TLR7
CCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.PMID 25252955Read ↗

Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.Semantic proximity Read ↗

Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.Semantic proximity Read ↗

TLR7-agonist and antineoplastic MEK1/2-inhibitor combination unlocks interferon responses from macrophagesSemantic proximity Read ↗

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Semantic proximity Read ↗

Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1Semantic proximity Read ↗

Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunitySemantic proximity Read ↗

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanomaSemantic proximity Read ↗

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responsesSemantic proximity Read ↗

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.Semantic proximity Read ↗

Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma CellsSemantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.